These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35858980)

  • 21. Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients.
    Wang CC; Kuo HC
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):279-284. PubMed ID: 29843924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
    Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
    BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
    Drake MJ; Chapple C; Esen AA; Athanasiou S; Cambronero J; Mitcheson D; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Herholdt C; MacDiarmid S;
    Eur Urol; 2016 Jul; 70(1):136-145. PubMed ID: 26965560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence.
    Özkidik M; Coşkun A; Asutay MK; Bahçeci T; Hamidi N
    Int Braz J Urol; 2019; 45(4):782-789. PubMed ID: 31136113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bladder overactivity induced by psychological stress in female mice is associated with enhanced bladder contractility.
    West EG; Sellers DJ; Chess-Williams R; McDermott C
    Life Sci; 2021 Jan; 265():118735. PubMed ID: 33166589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study.
    Inoue M; Yokoyama T
    Acta Med Okayama; 2019 Oct; 73(5):387-392. PubMed ID: 31649364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms-A randomized controlled trial.
    Chen HX; Chang SH; Chen DY; Lan JL; Yeo KJ; Huang PH; Huang CM; Huang CP; Chou EC; Wu PC
    Low Urin Tract Symptoms; 2023 Jul; 15(4):139-147. PubMed ID: 37191196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
    Gratzke C; van Maanen R; Chapple C; Abrams P; Herschorn S; Robinson D; Ridder A; Stoelzel M; Paireddy A; Yoon SJ; Al-Shukri S; Rechberger T; Mueller ER
    Eur Urol; 2018 Oct; 74(4):501-509. PubMed ID: 29866467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity.
    Svalø J; Nordling J; Bouchelouche K; Andersson KE; Korstanje C; Bouchelouche P
    Eur J Pharmacol; 2013 Jan; 699(1-3):101-5. PubMed ID: 23246623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
    Gratzke C; Chapple C; Mueller ER; Robinson D; Rolland C; Staskin D; Stoelzel M; Maanen RV; Siddiqui E
    Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Words of Wisdom. Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony).
    Cruz F
    Eur Urol; 2015 Jun; 67(6):1189-90. PubMed ID: 25944037
    [No Abstract]   [Full Text] [Related]  

  • 32. Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia.
    Sawada N; Nomiya M; Hood B; Koslov D; Zarifpour M; Andersson KE
    Eur Urol; 2013 Oct; 64(4):664-71. PubMed ID: 23838637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial.
    Kinjo M; Sekiguchi Y; Yoshimura Y; Nutahara K
    Low Urin Tract Symptoms; 2018 May; 10(2):148-152. PubMed ID: 27911988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY).
    Abrams P; Kelleher C; Staskin D; Kay R; Martan A; Mincik I; Newgreen D; Ridder A; Paireddy A; van Maanen R
    World J Urol; 2017 May; 35(5):827-838. PubMed ID: 27514371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term treatment with the beta-3 adrenoceptor agonist, mirabegron ameliorates detrusor overactivity and restores cyclic adenosine monophosphate (cAMP) levels in obese mice.
    Calmasini FB; de Oliveira MG; Alexandre EC; da Silva FH; da Silva CPV; Candido TZ; Antunes E; Mónica FZ
    Neurourol Urodyn; 2017 Aug; 36(6):1511-1518. PubMed ID: 27794199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The anxiolytic sertraline reduces the impact of psychological stress on bladder function in mice.
    West EG; Sellers DJ; Chess-Williams R; McDermott C
    Life Sci; 2021 Aug; 278():119598. PubMed ID: 33984361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison Of Solifenacin And Mirabegron For The Treatment Of Overactive Bladder.
    Jamil MN; Irum S; Islam EU
    J Ayub Med Coll Abbottabad; 2023; 35(2):298-300. PubMed ID: 37422825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.